Propanc Biopharma Inc (PPCB)

$2.87 -5.13 (-64.13%)
Market Cap 155,000.00
Revenue (ttm) 0.00
Net Income (ttm) -1.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.03
Volume 489,547
Avg Vol 2,732
Day's Range N/A - N/A
Shares Out 19,000.00
Stochastic %K 94%
Beta 2.78
Analysts Strong Buy
Price Target $12.50

Company Profile

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the r...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9882 0780
Fax: 61 3 9882 9969
Address:
302, 6 Butler Street, Camberwell, Australia
ShangVXO
ShangVXO Aug. 19 at 9:18 AM
Been tapped into @_ProfessorGamma for a minute now. The way they spot some of these plays before they run is nuts! Wise to be paying attention to this account, give him a proper follow 👍 $PPCB and $PMAX looks ready
1 · Reply
IR_propancbiopharma
IR_propancbiopharma Aug. 18 at 5:20 PM
Understanding how each part of a clinical development program fits together makes company milestones much easier to interpret. $PPCB
0 · Reply
MrTicker
MrTicker Aug. 18 at 12:31 PM
$PPCB Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRPAvance Clinical to Lead Preparatory Activities for Multi-Center Investigation Across Australia GLOBENEWSWIRE 7:30 AM ET 8/18/2026
0 · Reply
Casualtradess
Casualtradess Aug. 17 at 10:31 PM
$PPCB Has a High insider ownership may provide alignment..
0 · Reply
Casualtradess
Casualtradess Aug. 17 at 10:30 PM
$PPCB 💰 Tiny market cap = potentially huge upside if clinical news is positive!!
0 · Reply
Casualtradess
Casualtradess Aug. 17 at 10:26 PM
$PPCB why dip?
1 · Reply
IR_propancbiopharma
IR_propancbiopharma Aug. 17 at 4:29 PM
Clinical development involves much more than preparing for a trial. Scientific, manufacturing, regulatory, and technical work all contribute to building the program. $PPCB
0 · Reply
URANIUM77
URANIUM77 Aug. 14 at 7:07 PM
$HTZ $ADVB $PPCB $STKH $DFNS Don't forget the $5 million share buyback. Management believes the value is $20 per share. $PPCB
1 · Reply
URANIUM77
URANIUM77 Aug. 14 at 6:50 PM
$PPCB Free money on the street now Pick it up and Hold strong
0 · Reply
_AdulisTrades_
_AdulisTrades_ Aug. 14 at 4:49 PM
$ADVB $DFNS $HTZ $PPCB Closed out $STKH for 63% profit. Keeping the rest which are highly shorted and holding strong. Added AMIX today. The orange peel in chief is going to do something crazy over the weekend again to manipulate markets and get shorts margin called.
1 · Reply
Latest News on PPCB
Propanc Biopharma starts finalization of clinical trial protocol for PRP study

2026-08-18T12:50:18.000Z - 1 day ago

Propanc Biopharma starts finalization of clinical trial protocol for PRP study

Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP

Aug 18, 2026, 8:30 AM EDT - 1 day ago

Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP

Propanc highlights PRP as potential therapy against RAS-driven cancers

2026-08-17T09:24:22.000Z - 2 days ago

Propanc highlights PRP as potential therapy against RAS-driven cancers

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

Aug 12, 2026, 8:30 AM EDT - 7 days ago

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

Propanc reports new preclinical data for PRP in pancreatic ductal adenocarcinoma

2026-08-06T13:51:23.000Z - 13 days ago

Propanc reports new preclinical data for PRP in pancreatic ductal adenocarcinoma

Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models

Aug 6, 2026, 8:30 AM EDT - 13 days ago

Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models

Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program

Aug 5, 2026, 8:30 AM EDT - 14 days ago

Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program

Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal

Jul 21, 2026, 8:30 AM EDT - 4 weeks ago

Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal

Propanc Biopharma registers to sell 2.5M shares of common stock for holders

2026-07-17T21:35:21.000Z - 4 weeks ago

Propanc Biopharma registers to sell 2.5M shares of common stock for holders

Propanc Biopharma signs MOU with Avance Clinical for PRP clinical trial

2026-07-07T13:06:21.000Z - 6 weeks ago

Propanc Biopharma signs MOU with Avance Clinical for PRP clinical trial

Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd

Jul 7, 2026, 8:30 AM EDT - 6 weeks ago

Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd

Propanc Biopharma initiates share repurchase program

2026-07-02T12:55:35.000Z - 6 weeks ago

Propanc Biopharma initiates share repurchase program

Propanc Biopharma Initiates $5.0 Million Share Repurchase Program

Jul 2, 2026, 8:30 AM EDT - 6 weeks ago

Propanc Biopharma Initiates $5.0 Million Share Repurchase Program

Propanc CEO visits European manufacturer ahead of drug production plan

2026-06-16T13:41:11.000Z - 2 months ago

Propanc CEO visits European manufacturer ahead of drug production plan

Propanc Biopharma's CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study

Jun 16, 2026, 8:45 AM EDT - 2 months ago

Propanc Biopharma's CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study

Propanc Biopharma announces $5M share repurchase program

2026-06-11T13:14:59.000Z - 2 months ago

Propanc Biopharma announces $5M share repurchase program

Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program

Jun 11, 2026, 8:30 AM EDT - 2 months ago

Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program

Propanc Biopharma's CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain

Jun 2, 2026, 5:30 AM EDT - 2 months ago

Propanc Biopharma's CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain

Propanc Biopharma's CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade

May 20, 2026, 8:45 AM EDT - 3 months ago

Propanc Biopharma's CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade

Propanc Biopharma engages European CDMO for GMP production of PRP

2026-05-19T13:16:34.000Z - 3 months ago

Propanc Biopharma engages European CDMO for GMP production of PRP

Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients

May 19, 2026, 8:45 AM EDT - 3 months ago

Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients

Propanc Biopharma Inc trading halted, news pending

2026-05-15T23:51:01.000Z - 3 months ago

Propanc Biopharma Inc trading halted, news pending

Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results

May 15, 2026, 8:45 AM EDT - 3 months ago

Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results

Propanc Biopharma announces 1-for-25 reverse stock split

2026-05-14T09:34:08.000Z - 3 months ago

Propanc Biopharma announces 1-for-25 reverse stock split

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

May 13, 2026, 10:00 PM EDT - 3 months ago

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

Propanc Biopharma files to sell 15M shares of common stock for holders

2026-04-10T21:35:15.000Z - 4 months ago

Propanc Biopharma files to sell 15M shares of common stock for holders

Propanc Biopharma signs multi-year collaboration with Spanish universities

2026-03-24T13:11:19.000Z - 5 months ago

Propanc Biopharma signs multi-year collaboration with Spanish universities

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain

Mar 24, 2026, 8:45 AM EDT - 5 months ago

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain

Propanc Biopharma announces highlights of PRP

2026-03-12T13:04:12.000Z - 5 months ago

Propanc Biopharma announces highlights of PRP

Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

Mar 12, 2026, 8:45 AM EDT - 5 months ago

Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

Propanc Biopharma executes service agreement with FyoniBio

2026-03-10T12:51:18.000Z - 5 months ago

Propanc Biopharma executes service agreement with FyoniBio

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

Mar 10, 2026, 8:45 AM EDT - 5 months ago

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

Propanc Biopharma highlights potential of lead asset PRP

2026-03-03T13:59:37.000Z - 6 months ago

Propanc Biopharma highlights potential of lead asset PRP

Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

Mar 3, 2026, 8:45 AM EST - 6 months ago

Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

Propanc Biopharma provides corporate update

2026-02-18T13:50:25.000Z - 6 months ago

Propanc Biopharma provides corporate update

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

Feb 18, 2026, 8:45 AM EST - 6 months ago

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

Propanc Biopharma highlights potential of lead proenzyme therapy

2026-02-05T13:50:26.000Z - 6 months ago

Propanc Biopharma highlights potential of lead proenzyme therapy

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

Feb 5, 2026, 8:45 AM EST - 6 months ago

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

Propanc Biopharma files to sell 7M shares of common stock for holders

2026-02-02T22:35:25.000Z - 7 months ago

Propanc Biopharma files to sell 7M shares of common stock for holders

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

Jan 27, 2026, 8:45 AM EST - 7 months ago

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia

Jan 20, 2026, 8:45 AM EST - 7 months ago

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

Jan 15, 2026, 8:45 AM EST - 7 months ago

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

Propanc Biopharma Provides Shareholder Update

Jan 13, 2026, 8:45 AM EST - 7 months ago

Propanc Biopharma Provides Shareholder Update

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Dec 22, 2025, 7:00 AM EST - 8 months ago

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

Dec 4, 2025, 8:45 AM EST - 9 months ago

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

Dec 1, 2025, 8:45 AM EST - 9 months ago

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

Nov 17, 2025, 8:45 AM EST - 9 months ago

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline

Nov 10, 2025, 8:45 AM EST - 10 months ago

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

Nov 4, 2025, 7:00 AM EST - 10 months ago

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Oct 15, 2025, 5:45 PM EDT - 10 months ago

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Oct 15, 2025, 8:45 AM EDT - 11 months ago

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

Oct 7, 2025, 8:45 AM EDT - 11 months ago

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

Sep 17, 2025, 8:45 AM EDT - 1 year ago

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

Sep 2, 2025, 9:00 AM EDT - 1 year ago

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

Aug 19, 2025, 8:30 AM EDT - 1 year ago

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

Aug 14, 2025, 11:00 PM EDT - 1 year ago

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

ShangVXO
ShangVXO Aug. 19 at 9:18 AM
Been tapped into @_ProfessorGamma for a minute now. The way they spot some of these plays before they run is nuts! Wise to be paying attention to this account, give him a proper follow 👍 $PPCB and $PMAX looks ready
1 · Reply
IR_propancbiopharma
IR_propancbiopharma Aug. 18 at 5:20 PM
Understanding how each part of a clinical development program fits together makes company milestones much easier to interpret. $PPCB
0 · Reply
MrTicker
MrTicker Aug. 18 at 12:31 PM
$PPCB Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRPAvance Clinical to Lead Preparatory Activities for Multi-Center Investigation Across Australia GLOBENEWSWIRE 7:30 AM ET 8/18/2026
0 · Reply
Casualtradess
Casualtradess Aug. 17 at 10:31 PM
$PPCB Has a High insider ownership may provide alignment..
0 · Reply
Casualtradess
Casualtradess Aug. 17 at 10:30 PM
$PPCB 💰 Tiny market cap = potentially huge upside if clinical news is positive!!
0 · Reply
Casualtradess
Casualtradess Aug. 17 at 10:26 PM
$PPCB why dip?
1 · Reply
IR_propancbiopharma
IR_propancbiopharma Aug. 17 at 4:29 PM
Clinical development involves much more than preparing for a trial. Scientific, manufacturing, regulatory, and technical work all contribute to building the program. $PPCB
0 · Reply
URANIUM77
URANIUM77 Aug. 14 at 7:07 PM
$HTZ $ADVB $PPCB $STKH $DFNS Don't forget the $5 million share buyback. Management believes the value is $20 per share. $PPCB
1 · Reply
URANIUM77
URANIUM77 Aug. 14 at 6:50 PM
$PPCB Free money on the street now Pick it up and Hold strong
0 · Reply
_AdulisTrades_
_AdulisTrades_ Aug. 14 at 4:49 PM
$ADVB $DFNS $HTZ $PPCB Closed out $STKH for 63% profit. Keeping the rest which are highly shorted and holding strong. Added AMIX today. The orange peel in chief is going to do something crazy over the weekend again to manipulate markets and get shorts margin called.
1 · Reply
IR_propancbiopharma
IR_propancbiopharma Aug. 14 at 4:00 PM
$PPCB Long before an investigational treatment can be evaluated in a First-In-Human clinical study, multiple areas of work contribute to building the foundation for clinical development. Scientific validation, clinical planning, manufacturing preparation, regulatory preparation, and bioanalytical development each play a distinct role in this process. Over the coming weeks, we'll explore each of these areas, explaining why they matter and highlighting the publicly communicated milestones that have contributed to the development of PRP. Behind every clinical development program is a company executing across multiple scientific, technical, and operational disciplines. Understanding how these areas work together provides broader context for the milestones that support the development of PRP. $PPCB
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Aug. 13 at 10:30 PM
While emerging RAS-targeted therapies focus on inhibiting oncogenic signaling, Propanc's PRP is designed to operate differently: promoting cancer cell differentiation, reversing EMT, and targeting cancer stem cells associated with recurrence, resistance, and metastasis. PRP is not mutation-specific, potentially positioning its non-cytotoxic, proenzyme-based mechanism as a complementary approach for aggressive solid tumors. Recent preclinical PDAC data showed >90% mean tumor growth inhibition, reduced metastatic burden, and >2.5x extension of median overall survival versus controls. Now, the focus moves to clinical execution. Propanc expects to file its Clinical Trial Application for the planned Phase 1b study in Q4 2026. The next step: bringing PRP into the clinic. $PPCB
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Aug. 12 at 8:07 PM
More than 2 million Americans are expected to be diagnosed with cancer this year alone. Those numbers are more than statistics—they're the reason companies like $PPCB continue working to advance new therapeutic approaches.
0 · Reply
_AdulisTrades_
_AdulisTrades_ Aug. 12 at 5:18 PM
$HTZ $ADVB $PPCB $STKH $DFNS Check back in 7-10 days. 🔥⏫️
0 · Reply
URANIUM77
URANIUM77 Aug. 12 at 1:13 PM
$PPCB Big news today 💪💪💰💰 Buyback $5 Mini float TARGET $20 IS COMING
0 · Reply
MrTicker
MrTicker Aug. 12 at 12:33 PM
$PPCB Propanc Biopharma Says It Expects To File Clinical Trial Application For Phase 1b Study Of PRP In Advanced Cancer Patients In Q4 2026 BENZINGA 7:32 AM ET 8/12/2026
0 · Reply
URANIUM77
URANIUM77 Aug. 11 at 7:35 PM
$PPCB Target 15
0 · Reply
URANIUM77
URANIUM77 Aug. 11 at 2:48 PM
$PPCB Yess Load up and Hold
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Aug. 11 at 1:39 PM
Strong science creates value when it moves a program forward. That's why $PPCB's latest preclinical results matter—they reinforce the path toward the clinic.
0 · Reply
Jags1000
Jags1000 Aug. 11 at 9:14 AM
$PPCB os a 10x possible here?
1 · Reply
URANIUM77
URANIUM77 Aug. 10 at 7:39 PM
$PPCB OMG CTB loan interest on short stocks passes 400% now https://fintel.io/ss/us/ppcb
0 · Reply
URANIUM77
URANIUM77 Aug. 10 at 7:32 AM
$PPCB loading zone now :)
0 · Reply